Literature DB >> 9815737

Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.

G A Waanders1, D Rimoldi, D Liénard, S Carrel, F Lejeune, P Y Dietrich, J C Cerottini, P Romero.   

Abstract

The expression by melanomas of multiple antigens that are recognized by specific MHC class I-restricted CTLs has been clearly demonstrated. The goal of many immunotherapy protocols being developed is, therefore, the induction and/or augmentation of CTLs specific for such antigens. One approach has been to immunize using irradiated autologous melanoma cells. Responses to this type of immunization and others are often subsequently measured by delayed-type hypersensitivity (DTH) reactions. The aim of this work was to characterize whether specific CTL responses occur at such DTH sites. Cutaneous DTH reactions were observed following injection of irradiated autologous melanoma cells expressing known tumor antigens. We isolated lymphocytes from biopsies of DTH reaction sites and could measure melanoma-specific CTL activity after 2-3 weeks of culture. The T-cell receptor-Vbeta repertoire of the cultured lymphocytes, assessed by flow cytometry, was highly skewed in both the CD4(+) and CD8(+) T-cell subsets. The repertoires were different among cultures derived from independent biopsies of simultaneous or subsequent DTH reaction sites and very different to that of fresh peripheral blood lymphocytes (PBLs) or PBLs cultured under the same conditions. No particular T-cell expansions dominated several DTH reaction sites, nor could they be detected in PBLs. It appears that T-cell responses to this type of immunization may be limited to the local microenvironment. Establishing the value of DTH reactions in determining levels of systemic antitumor immunity requires further investigation; however, such reactions may indicate a patient's competence to mount an antitumor immune response and enable the isolation of tumor-specific CTLs for use in tumor antigen identification.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815737

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  4 in total

1.  Triggering DTH and CTL activity by fd filamentous bacteriophages: role of CD4+ T cells in memory responses.

Authors:  Giovanna Del Pozzo; Dina Mascolo; Rossella Sartorius; Alessandra Citro; Pasquale Barba; Luciana D'Apice; Piergiuseppe De Berardinis
Journal:  J Biomed Biotechnol       Date:  2010-04-29

Review 2.  Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2011-04-26

3.  Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.

Authors:  M Lotem; E Shiloni; I Pappo; O Drize; T Hamburger; R Weitzen; R Isacson; L Kaduri; S Merims; S Frankenburg; T Peretz
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

4.  Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.

Authors:  M Lotem; T Peretz; O Drize; Z Gimmon; D Ad El; R Weitzen; H Goldberg; I Ben David; D Prus; T Hamburger; E Shiloni
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.